AbbVie to Present at the Morgan Stanley Healthcare Conference
Get Alerts ABBV Hot Sheet
Join SI Premium – FREE
NORTH CHICAGO, Ill., Sept. 7, 2022 /PRNewswire/ -- AbbVie (NYSE: ABBV) will participate in the Morgan Stanley 20th Annual Global Healthcare Conference on Tuesday, September 13, 2022. Rob Michael, vice chairman and president, Jeff Stewart, executive vice president, commercial operations, and Neil Gallagher, vice president development and chief medical officer will present at 9:35 a.m. Central time.
A live audio webcast of the presentation will be accessible through AbbVie's Investor Relations website at investors.abbvie.com. An archived edition of the session will be available later that day.
About AbbVie
AbbVie's mission is to discover and deliver innovative medicines that solve serious health issues today and address the medical challenges of tomorrow. We strive to have a remarkable impact on people's lives across several key therapeutic areas: immunology, oncology, neuroscience, eye care, virology, women's health and gastroenterology, in addition to products and services across its Allergan Aesthetics portfolio. For more information about AbbVie, please visit us at www.abbvie.com. Follow @abbvie on Twitter, Facebook, Instagram, YouTube and LinkedIn.
View original content:https://www.prnewswire.com/news-releases/abbvie-to-present-at-the-morgan-stanley-healthcare-conference-301618670.html
SOURCE AbbVie
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- The Apex Institute Reveals What Hiring Managers Actually Want in Cloud and AI Infrastructure Roles
- XTEP Unveils World-Class Dual Flagship Running Shoes, Ushering China's Running Footwear into a New Era of Full-Scenario Running
- Orum Therapeutics Announces U.S. FDA Clearance of an IND Application for ORM-1153, a Novel CD123-GSPT1 Degrader-Antibody Conjugate
Create E-mail Alert Related Categories
PRNewswire, Press ReleasesRelated Entities
Morgan Stanley, TwitterSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!



Tweet
Share